Predicta Biosciences raised $5.2M in a seed round led by The Engine Ventures to transform the diagnosis, treatment and monitoring of blood cancers.
Predicta Biosciences raised $5.2M in a seed round led by The Engine Ventures to transform the diagnosis, treatment and monitoring of blood cancers.
07/16/24, 12:04 PM
Location
bostonMoney raised
$5.2 million
Industry
health diagnostics
therapeutics
medical
biotechnology
health care
Round Type
seed
Investors
Oetgen Family, American Cancer Society Bright Edge, Time Boost Capital, Illumina Ventures, The Engine Ventures
Predicta Biosciences, a precision oncology company, announced an oversubscribed $5.2 million seed round led by The Engine Ventures, with additional participation from Illumina Ventures, Time Boost Capital, the American Cancer Society Bright Edge, and the Oetgen family. The company will use the seed funding to expand its team, and build a CLIA lab and workflow for sequencing and bioinformatics.
Company Info
Location
boston, massachusetts, united states
Additional Info
Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.